OncoSec Medical CEO Punit Dhillon to Host Live Webinar to Provide Corporate Update and 2015 Outlook
SAN DIEGO-- OncoSec Medical Inc. (“OncoSec”) (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced it will provide a comprehensive corporate update and Q&A session for investors and the general public during a webinar starting at 9:30 AM PDT on Monday, March 23, 2015.
Punit Dhillon, President and CEO, will host the webinar to provide an engaging, educational discussion regarding the company and its outlook for the upcoming year. Attendees will hear first-hand from the CEO as he shares updates on several pertinent topics, including: clinical trials timeline, research activities, development of new electroporation devices, financial updates, and current market opportunity in the cancer immunotherapy landscape.
The company will also address questions from the public during the webinar’s Q&A session. OncoSec encourages people to submit their questions prior to the webinar via OncoSec’s social media channels: Twitter (https://twitter.com/oncosec) and Facebook (https://www.facebook.com/oncosecmedical).
To register for the event, please click on the following link at any time prior to the webinar: https://attendee.gotowebinar.com/register/4040606641159991809. Please register at least 10 minutes prior to the start of the presentation to ensure timely access. After registering, you will receive a confirmation email containing information about joining the webinar.
For technical assistance, please contact Go To Webinar at 855-352-9002. For those unable to attend to the live webinar, an archive version will be available for 90 days on OncoSec’s website: http://www.oncosec.com.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec’s core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. OncoSec’s lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase II development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Source: OncoSec Medical Inc.
Released March 17, 2015